{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:08:11Z","timestamp":1792069691349,"version":"4.4.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":124,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.prdoa.2020.100056","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T17:46:22Z","timestamp":1588787182000},"page":"100056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Huntington disease: Advances in the understanding of its mechanisms"],"prefix":"10.1016","volume":"3","author":[{"given":"Emilia M.","family":"Gatto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Gonz\u00e1lez","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Persi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Etcheverry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn Emiliano","family":"Cesarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Perandones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2020.100056_bb0005","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington\u2019s disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prdoa.2020.100056_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-71779-1_1","article-title":"Clinical features of Huntington\u2019s disease","volume":"1049","author":"Ghosh","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/mds.27640","article-title":"Juvenile Huntington Disease Working Group of the European Huntington Disease Network. Defining pediatric Huntington disease: time to abandon the term juvenile Huntington disease?","volume":"34","author":"Quarrell","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2020.100056_bb0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1590\/0004-282X20150192","article-title":"Juvenile Huntington disease in Argentina","volume":"74","author":"Gatto","year":"2016","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.prdoa.2020.100056_bb0025","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(18)30294-1","article-title":"Biological and clinical manifestations of juvenile Huntington\u2019s disease: a retrospective analysis","volume":"17","author":"Fusilli","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3233\/JHD-160185","article-title":"Phenotype characterization of HD intermediate alleles in PREDICT-HD","volume":"5","author":"Downing","year":"2016","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.prdoa.2020.100056_bb0035","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1212\/WNL.0000000000002944","article-title":"European HD Network. Clinical manifestations of intermediate allele carriers in Huntington disease","volume":"87","author":"Cubo","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2020.100056_bb0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0045","first-page":"31","article-title":"Epidemiology of Huntington disease","author":"Kay","year":"2017","journal-title":"Handb. Clin. Neurol."},{"issue":"10","key":"10.1016\/j.prdoa.2020.100056_bb0050","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"issue":"453","key":"10.1016\/j.prdoa.2020.100056_bb0055","first-page":"1","article-title":"Genetic counseling in Huntington\u2019s disease: potential new challenges on horizon?","volume":"10","author":"Migliore","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.prdoa.2020.100056_bb0060","doi-asserted-by":"crossref","first-page":"e2101","DOI":"10.1212\/WNL.0000000000007147","article-title":"European HD Network. Clinical manifestations of homozygote allele carriers in Huntington disease","volume":"92","author":"Cubo","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2020.100056_bb0065","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1093\/hmg\/ddx261","article-title":"Genetic modifiers of Mendelian disease: Huntington\u2019s disease and the trinucleotide repeat disorders","volume":"26","author":"Holmans","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.prdoa.2020.100056_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40142-018-0133-1","article-title":"Genetic modifiers in neurodegeneration","volume":"6","author":"Jain","year":"2018","journal-title":"Curr Genet Med Rep."},{"key":"10.1016\/j.prdoa.2020.100056_bb0075","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/hmg\/ddy375","article-title":"FAN1 modifies Huntington\u2019s disease progression by stabilizing the expanded HTT CAG repeat","volume":"28","author":"Goold","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.prdoa.2020.100056_bb0080","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"TRACK-HD Investigators. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data","volume":"7","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0085","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/mds.26364","article-title":"PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Multivariate prediction of motor diagnosis in Huntington\u2019s disease: 12 years of PREDICT-HD","volume":"12","author":"Long","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2020.100056_bb0090","doi-asserted-by":"crossref","first-page":"E8765","DOI":"10.1073\/pnas.1807962115","article-title":"Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition","volume":"115","author":"Siebzehnr\u00fcbl","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.prdoa.2020.100056_bb0095","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/hmg\/ddg075","article-title":"Transgenic rat model of Huntington\u2019s disease","volume":"12","author":"von H\u00f6rsten","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.prdoa.2020.100056_bb0100","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1523\/JNEUROSCI.16-17-05523.1996","article-title":"Expression of normal and mutant huntingtin in the developing brain","volume":"16","author":"Bhide","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/cpns.47","article-title":"Overview of Huntington\u2019s disease models: neuropathological, molecular, and behavioral differences","volume":"83","author":"Rangel-Barajas","year":"2018","journal-title":"Curr Protoc Neurosci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ydbio.2015.07.013","article-title":"Huntingtin is required for ciliogenesis and neurogenesis during early Xenopus development","volume":"408","author":"Haremaki","year":"2015","journal-title":"Dev. Biol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0115","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3389\/fncel.2018.00528","article-title":"Identification of altered developmental pathways in human juvenile HD iPSC with 71Q and 109Q using transcriptome profiling","volume":"12","author":"\u015awito\u0144ska","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nn.4532","article-title":"Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice","volume":"5","author":"HD iPSC Consortium","year":"2017","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.prdoa.2020.100056_bb0125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neuropharm.2018.03.009","article-title":"Huntingtin protein: a new option for fixing the Huntington\u2019s disease countdown clock","volume":"135","author":"Caterino","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.prdoa.2020.100056_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.121","article-title":"An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity","volume":"3","author":"Cisbani","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.prdoa.2020.100056_bb0135","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1172\/JCI45364","article-title":"The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease","volume":"121","author":"Munoz-Sanjuan","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prdoa.2020.100056_bb0140","first-page":"1","article-title":"Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease","author":"Franco-Iborra","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.prdoa.2020.100056_bb0145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/14728222.2018.1465930","article-title":"Huntington\u2019s disease: novel therapeutic perspectives hanging in the balance","volume":"22","author":"Saavedra","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.prdoa.2020.100056_bb0150","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/WNL.0000000000000440","article-title":"Epigenetic regulation: basic concepts and relevance to neurologic disease","volume":"82","author":"Klein","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2020.100056_bb0155","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fnmol.2017.00382","article-title":"Intracellular cholesterol trafficking and impact in neurodegeneration","volume":"10","author":"Arenas","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnhum.2017.00017","article-title":"Contribution of neuroepigenetics to Huntington\u2019s disease","volume":"11","author":"Francelle","year":"2017","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-319-53889-1_15","article-title":"Epigenetics of Huntington\u2019s disease","volume":"978","author":"Bassi","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuropharm.2013.10.025","article-title":"What\u2019s wrong with epigenetics in Huntington\u2019s disease?","volume":"80","author":"Valor","year":"2014","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.prdoa.2020.100056_bb0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/bs.pmbts.2017.11.013","article-title":"Sirtuins as modifiers of Huntington\u2019s disease (HD) pathology","volume":"154","author":"Neo","year":"2018","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0180","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/cr.2013.70","article-title":"Sirtuin deacetylases in neurodegenerative diseases of aging","volume":"23","author":"Herskovits","year":"2013","journal-title":"Cell Res."},{"key":"10.1016\/j.prdoa.2020.100056_bb0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","article-title":"Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration","volume":"127","author":"Cui","year":"2006","journal-title":"Cell."},{"key":"10.1016\/j.prdoa.2020.100056_bb0190","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/febs.13148","article-title":"Sp1 and the \u2018hallmarks of cancer\u2019","volume":"282","author":"Beishline","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.prdoa.2020.100056_bb0195","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.conb.2017.12.008","article-title":"REST, a master transcriptional regulator in neurodegenerative disease","volume":"48","author":"Hwang","year":"2018","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0200","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pneurobio.2017.03.008","article-title":"Synaptopathic mechanisms of neurodegeneration and dementia: insights from Huntington\u2019s disease","volume":"153","author":"Tyebji","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jnc.14723","article-title":"Alterations in synaptic function and plasticity in Huntington disease","volume":"150","author":"Smith-Dijak","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.prdoa.2020.100056_bb0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fncel.2019.00103","article-title":"Mitochondrial dysfunction in Huntington\u2019s disease; interplay between HSF1, p53 and PGC-1\u03b1 transcription factors","volume":"13","author":"Intihar","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0215","first-page":"132","article-title":"Emerging role of non-coding RNA in neural plasticity, cognitive function, and neuropsychiatric disorders","volume":"3","author":"Padaro","year":"2012","journal-title":"Front. Genet."},{"key":"10.1016\/j.prdoa.2020.100056_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051310","article-title":"Noncoding RNA:RNA regulatory networks in cancer","volume":"19","author":"Chan","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.prdoa.2020.100056_bb0225","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1051\/jbio:2005026","article-title":"Huntington\u2019s disease: intracellular signaling pathways and neuronal death","volume":"199","author":"Humbert","year":"2005","journal-title":"J Soc Biol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0230","doi-asserted-by":"crossref","first-page":"E10809","DOI":"10.1073\/pnas.1705372114","article-title":"Phosphorylation of huntingtin at residue T3 is decreased in Huntington\u2019s disease and modulates mutant huntingtin protein conformation","volume":"114","author":"Cariulo","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2018","key":"10.1016\/j.prdoa.2020.100056_bb0235","doi-asserted-by":"crossref","first-page":"18540","DOI":"10.1074\/jbc.RA118.004621","article-title":"N-terminal Huntingtin (Htt) phosphorylation is a molecular switch regulating Htt aggregation, helical conformation, internalization, and nuclear targeting","volume":"293","author":"DeGuire","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prdoa.2020.100056_bb0240","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/emboj.2008.133","article-title":"Huntingtin phosphorylation acts as a molecular switch for anterograde\/retrograde transport in neurons","volume":"27","author":"Colin","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.prdoa.2020.100056_bb0245","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrm.2017.20","article-title":"The HSP90 chaperone machinery","volume":"18","author":"Schopf","year":"2017","journal-title":"Nat Rev Mol Cell Biol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0250","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron."},{"key":"10.1016\/j.prdoa.2020.100056_bb0255","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1073\/pnas.1402215111","article-title":"Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A","volume":"111","author":"Bhat","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prdoa.2020.100056_bb0260","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41419-019-1451-2","article-title":"Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1(G93A) model","volume":"10","author":"Ionescu","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.prdoa.2020.100056_bb0265","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.tips.2016.01.003","article-title":"The sigma-1 receptor as a pluripotent modulator in living systems","volume":"37","author":"Su","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0270","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fmolb.2019.00020","article-title":"Protein misfolding and ER stress in Huntington\u2019s disease","volume":"6","author":"Shacham","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0275","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/aps.2018.11","article-title":"Proteostasis in Huntington\u2019s disease: disease mechanisms and therapeutic opportunities","volume":"39","author":"Harding","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.prdoa.2020.100056_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030728","article-title":"Balancing mTOR signaling and autophagy in the treatment of Parkinson\u2019s disease","volume":"20","author":"Zhu","year":"2019","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0285","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1523\/JNEUROSCI.1870-13.2014","article-title":"The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation","volume":"34","author":"Wong","year":"2014","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.prdoa.2020.100056_bb0290","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tins.2014.09.003","article-title":"Autophagy in Huntington disease and huntingtin in autophagy","volume":"38","author":"Martin","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0295","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","article-title":"Huntington\u2019s disease: underlying molecular mechanisms and emerging concepts","volume":"38","author":"Labbadia","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13041-019-0456-1","article-title":"Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington\u2019s pathology in zQ175 mice","volume":"12","author":"Abd-Elrahman","year":"2019","journal-title":"Mol Brain."},{"key":"10.1016\/j.prdoa.2020.100056_bb0305","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1212\/WNL.0000000000000922","article-title":"mTOR: its role in the nervous system and involvement in neurologic disease","volume":"83","author":"Child","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2020.100056_bb0310","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-319-71779-1_3","article-title":"Mitochondrial dysfunction in Huntington\u2019s disease","volume":"1049","author":"Carmo","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0315","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/emboj.2012.65","article-title":"Shaping the role of mitochondria in the pathogenesis of Huntington\u2019s disease","volume":"31","author":"Costa","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.prdoa.2020.100056_bb0320","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fnins.2018.00342","article-title":"Mitochondrial quality control in neurodegenerative diseases: focus on Parkinson\u2019s disease and Huntington\u2019s disease","volume":"12","author":"Franco-Iborra","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0325","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1042\/BCJ20160627","article-title":"Protein trafficking in the mitochondrial intermembrane space: mechanisms and links to human disease","volume":"474","author":"MacPherson","year":"2017","journal-title":"Biochem. J."},{"key":"10.1016\/j.prdoa.2020.100056_bb0330","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/nrm3013","article-title":"Mitochondrial fusion and fission in cell life and death","volume":"11","author":"Westermann","year":"2010","journal-title":"Nat Rev Mol Cell Biol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0335","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bbrc.2016.08.042","article-title":"Mitochondrial fragmentation in neuronal degeneration: toward an understanding of HD striatal susceptibility","volume":"483","author":"Cherubini","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.prdoa.2020.100056_bb0340","article-title":"Removal of the mitochondrial fission factor Mff exacerbates neuronal loss and neurological phenotypes in a Huntington\u2019s disease mouse model","volume":"10","author":"Cha","year":"2018","journal-title":"PLoS Curr"},{"key":"10.1016\/j.prdoa.2020.100056_bb0345","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JHD-180324","article-title":"Huntingtin aggregates and mitochondrial pathology in skeletal muscle but not heart of late-stage R6\/2 mice","volume":"8","author":"Kojer","year":"2019","journal-title":"J Huntingtons Dis."},{"key":"10.1016\/j.prdoa.2020.100056_bb0350","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bbrc.2018.01.114","article-title":"Drp1 phosphorylation by MAPK1 causes mitochondrial dysfunction in cell culture model of Huntington\u2019s disease","volume":"496","author":"Roe","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.prdoa.2020.100056_bb0355","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuroscience.2016.03.031","article-title":"Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin","volume":"325","author":"Connolly","year":"2016","journal-title":"Neuroscience."},{"key":"10.1016\/j.prdoa.2020.100056_bb0360","doi-asserted-by":"crossref","first-page":"9622","DOI":"10.1073\/pnas.1818042116","article-title":"Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease","volume":"116","author":"Bardile","year":"2019","journal-title":"PNAS"},{"key":"10.1016\/j.prdoa.2020.100056_bb0365","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"10.1016\/j.prdoa.2020.100056_bb0370","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nchembio.1790","article-title":"siRNA screen identifies QPCT as a druggable target for Huntington\u2019s disease","volume":"11","author":"Jimenez-Sanchez","year":"2015","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.prdoa.2020.100056_bb0375","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuint.2018.07.003","article-title":"Recent advances in the mechanisms of neuroinflammation and their roles in neurodegeneration","volume":"120","author":"Niranjan","year":"2018","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.prdoa.2020.100056_bb0380","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.bbamcr.2010.12.012","article-title":"The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation","volume":"1813","author":"Plotnikov","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.prdoa.2020.100056_bb0385","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tips.2018.02.009","article-title":"The S1P axis: new exciting route for treating Huntington\u2019s disease","volume":"39","author":"DiPardo","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.prdoa.2020.100056_bb0390","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbadis.2016.12.015","article-title":"Visualization of prion-like transfer in Huntington\u2019s disease models","volume":"1863","author":"Jansen","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.prdoa.2020.100056_bb0395","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnana.2011.00043","article-title":"Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons","volume":"5","author":"Nishi","year":"2011","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.prdoa.2020.100056_bb0400","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington\u2019s disease models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.prdoa.2020.100056_bb0405","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.neuroimage.2017.02.047","article-title":"Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D(2\/3) receptors and sub-cortical volumes in the human basal ganglia: a PET study with (18)F-MNI-659 and (11)C-raclopride with correction for partial volume effect","volume":"152","author":"Fazio","year":"2017","journal-title":"Neuroimage."},{"key":"10.1016\/j.prdoa.2020.100056_bb0410","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrneurol.2015.148","article-title":"Neurodegenerative disease: changes in brain phosphodiesterase 10A levels in neurodegenerative basal ganglia disorders","volume":"11","author":"Wood","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0415","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neulet.2018.08.006","article-title":"PET radioligands for imaging of the PDE10A in human: current status","volume":"691","author":"Boscutti","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.prdoa.2020.100056_bb0420","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/mds.27219","article-title":"A familial case of PDE10A-associated childhood-onset chorea with bilateral striatal lesions","volume":"33","author":"Miyatake","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2020.100056_bb0425","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/mds.27175","article-title":"A PDE10A de novo mutation causes childhood-onset chorea with diurnal fluctuations","volume":"32","author":"Esposito","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.prdoa.2020.100056_bb0430","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ajmg.a.38507","article-title":"Familial choreoathetosis due to novel heterozygous mutation in PDE10A","volume":"176","author":"Narayanan","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.prdoa.2020.100056_bb0435","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1007\/s00018-019-03059-8","article-title":"Phosphorylated and aggregated TDP-43 with seeding properties are induced upon mutant Huntingtin (mHtt) polyglutamine expression in human cellular models","volume":"76","author":"Coudert","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.prdoa.2020.100056_bb0440","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41374-018-0166-9","article-title":"Spectrum of tau pathologies in Huntington\u2019s disease","volume":"99","author":"Baskota","year":"2019","journal-title":"Lab. Investig."},{"key":"10.1016\/j.prdoa.2020.100056_bb0445","doi-asserted-by":"crossref","first-page":"19180","DOI":"10.1038\/srep19180","article-title":"\u03b1-Synuclein and huntingtin exon 1 amyloid fibrils bind laterally to the cellular membrane","volume":"6","author":"Monsellier","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.prdoa.2020.100056_bb0450","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","article-title":"Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease","volume":"135","author":"St-Amour","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.prdoa.2020.100056_bb0455","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1212\/WNL.0000000000003725","article-title":"Low cancer prevalence in polyglutamine expansion diseases","volume":"88","author":"Coarelli","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2020.100056_bb0460","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.trecan.2018.08.004","article-title":"Trinucleotide repeat expansion diseases, RNAi, and cancer","volume":"4","author":"Murmann","year":"2018","journal-title":"Trends Cancer."},{"key":"10.1016\/j.prdoa.2020.100056_bb0465","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201745336","article-title":"Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells","volume":"19","author":"Murmann","year":"2018","journal-title":"EMBO Rep"}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112520300244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112520300244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:46:36Z","timestamp":1762911996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112520300244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":93,"alternative-id":["S2590112520300244"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2020.100056","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Huntington disease: Advances in the understanding of its mechanisms","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2020.100056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100056"}}